Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 5, 2011, Pages 376-381

  Huang, Chi Chang ^a   Wu, Chi Jung ^a,b   Wang, Li Rong ^a   Lee, Hsin Chun ^a   Chang, Chia Ming ^a   Lee, Nan Yao ^a   Chen, Tsai Yun ^a   Ko, Wen Chien ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Antimicrobial susceptibility; Bacteremia; Malignancy; Neutropenia

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFEPIME; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CANCER PATIENT; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISK DIFFUSION; ENTEROBACTER CLOACAE; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TAIWAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIA; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TAIWAN; YOUNG ADULT;

EID: 80053620310     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.01.035     Document Type: Article

References (27)

1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
2. Wisplinghoff H., Cornely O.A., Moser S., Bethe U., Stützer H., Salzberger B. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol 2003, 24:905-911.
3. Basu S.K., Fernandez I.D., Fisher S.G., Asselin B.L., Lyman G.H. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005, 23:7958-7966.
4. Velasco E., Byington R., Martins C.A., Schirmer M., Dias L.M., Gonçalves V.M. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 2006, 25:1-7.
5. Wisplinghoff H., Seifert H., Wenzel R.P., Edmond M.B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003, 37:1144-1145.
6. Chen C.-Y., Tsay W., Tang J.-L., Tien H.-F., Chen Y.-C., Chang S.C., et al. Epidemiology of bloodstream infections in patients with haemaological malignancies with and without neutropenia. Epidemiol Infect 2009, 27:1-8.
7. Dellinger R.P., Levy M.M., Carlet J.M. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008, 2008(34):783-785.
8. Bochud P.Y., Bonten M., Marchetti O., Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32:495-512.
9. Guideline for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect 2005, 38:455-457. Infectious Diseases Society of Taiwan, Hematology Society of TaiwanHematology Society of Taiwan, Medical Foundation in Memory Dr. Deh-Lin ChengMedical Foundation in Memory Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and EducationFoundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, CY Lee's Research Foundation for Pediatric Infectious Diseases and VaccineCY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine.
10. Miller J.M., O'Hara C.M. Substrate utilization systems for the identification of bacteria and yeast. Manual of clinical microbiology 1995, 103-109. American Society for Microbiology, Washington, D.C. P.R. Murray, E.J. Baron (Eds.).
11. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 15th informational supplement. M100-S15 2005, Clinical and Laboratory Standards Institute, Wayne, PA.
12. Brown S.D., Traczewski M.M. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbio1 2007, 45:2173-2179.
13. Pharmaceuticals Wyeth Tygacil (tigecycline) for injection 2005, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
14. Jones R.N., Thornsberry C., Barry A.L., Ayers L., Brown S., Daniel J., et al. Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR 810, a fourth-generation cephalosporin, in clinical microbiology laboratories. J Clin Microbiol 1984, 20:409-412.
15. Jones R.N., Barry A.L., Thornsberry Clyde Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media. Diagn Microbiol Infect Dis 1986, 4:345-349.
16. Del Favero A., Menichetti F., Martino P., Bucaneve G., Micozzi A., et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001, 33:1295-1301.
17. González-Barca E., Fernández-Sevilla A., Carratalá J., Salar A., Peris J., Grañena A., et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 1999, 18:539-544.
18. Cordonnier C., Buzyn A., Leverger G., Herbrecht R., Hunault M., Leclercq R., et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003, 36:149-158.
19. Wang F.D., Lin M.L., Liu C.Y. Bacteremia in patients with hematological malignancies. Chemotherapy 2005, 51:147-153.
20. Vardakas K.Z., Samonis G., Chrysanthopoulou S.A., Bliziotis I.A., Falagas M.E. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:431-439.
21. Bhat S., Fujitani S., Potoski B.A., Capitano B., Linden P.K., Shutt K., et al. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?. Int J Antimicrob Agents 2007, 30:458-462.
22. Furno P., Bucaneve G., Del Favero A. Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002, 2:231-242.
23. Paul M., Soares-Weiser K., Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003, 326:1111.
24. Safdar N., Handelsman J., Maki D.G. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527.
25. Chamot E., Boffi El Amari E., Rohner P., Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003, 47:2756-2764.
26. Burgess D.S. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005, 40:99-104.
27. Drago L., De Vecchi E., Nicola L., Tocalli L., Gismondo M.R. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother 2005, 56:353-359.